MILLSBORO, DEL. - Intervet introduces PreveNile, a modified-live virus (MLV) vaccine for West Nile Virus (WNV) in horses.
MILLSBORO, DEL. — Intervet introduces PreveNile, a modified-live virus (MLV) vaccine for West Nile Virus (WNV) in horses.
The product is a one-dose preventative available for primary immunization and features a comprehensive label claim.
The product is approved by the United States Department of Agriculture, labeled for prevention of viremia and as an aid in the prevention of diseases and encephalitis caused by WNV.
PreveNile was tested at the University of Florida by Dr. Maureen Long using a severe intrathecal challenge model that causes viremia and clinical signs of disease consistant with those observed in horses naturally infected with WNV under field conditions.
The product was shown to be 95-percent effective and shown to reduce clinical signs of WNV in horses vaccinated with a single dose as compared to unvaccinated horses, Long says.
Vaccination resulted in 100-percent survivorship in a single dose and statistically significant reduction in clinical signs of WNV disease.
For fastest response, call